Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedMinor site revision updated from v3.4.1 to v3.4.2; no study content, eligibility criteria, or user-facing actions were changed.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1.SummaryDifference0.0%

- Check32 days agoChange DetectedUI and metadata updates include the glossary toggle options (Show glossary, Hide glossary) and a new revision tag (Revision: v3.4.0). The page also updates timestamp-related labels (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data) and removes older labels (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).SummaryDifference0.1%

- Check40 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4, a minor metadata change with no visible impact on content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedExpanded the study's Locations section with a wide array of new sites across multiple countries and regions (examples include Argentina, Australia, Belgium, Brazil, Canada, China, France, Germany, Greece, Japan, Mexico, the Netherlands, Spain, the United Kingdom, and the United States).SummaryDifference3%

- Check90 days agoChange DetectedNon-significant editorial updates were made: the page now explains that publications are automatically filled from PubMed and the revision was updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.